MX2023006542A - Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo. - Google Patents

Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.

Info

Publication number
MX2023006542A
MX2023006542A MX2023006542A MX2023006542A MX2023006542A MX 2023006542 A MX2023006542 A MX 2023006542A MX 2023006542 A MX2023006542 A MX 2023006542A MX 2023006542 A MX2023006542 A MX 2023006542A MX 2023006542 A MX2023006542 A MX 2023006542A
Authority
MX
Mexico
Prior art keywords
vitiligo
treatment
pathway inhibitors
jak1 pathway
jak1
Prior art date
Application number
MX2023006542A
Other languages
English (en)
Inventor
James Lee
Paul Smith
Michael D Howell
Kurt Andrew Brown
Fiona Kuo
Santos Leandro Luiz Dos
Beth Rumberger
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2023006542A publication Critical patent/MX2023006542A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se relaciona con inhibidores de la vía JAK1 y su uso para tratar el vitiligo.
MX2023006542A 2020-12-08 2021-12-08 Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo. MX2023006542A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122574P 2020-12-08 2020-12-08
US202163246688P 2021-09-21 2021-09-21
PCT/US2021/062419 WO2022125670A1 (en) 2020-12-08 2021-12-08 Jak1 pathway inhibitors for the treatment of vitiligo

Publications (1)

Publication Number Publication Date
MX2023006542A true MX2023006542A (es) 2023-08-25

Family

ID=79283140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006542A MX2023006542A (es) 2020-12-08 2021-12-08 Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.

Country Status (11)

Country Link
US (1) US11957661B2 (es)
EP (1) EP4259131A1 (es)
JP (1) JP2023552452A (es)
KR (1) KR20230118118A (es)
AU (1) AU2021396231A1 (es)
CA (1) CA3204374A1 (es)
CL (1) CL2023001637A1 (es)
IL (1) IL303238A (es)
MX (1) MX2023006542A (es)
TW (1) TW202237089A (es)
WO (1) WO2022125670A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007805SA (en) 2018-02-16 2020-09-29 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0515775Y2 (es) 1987-07-13 1993-04-26
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
HUP0401982A3 (en) 2001-09-19 2012-09-28 Aventis Pharma Sa Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
DK1441737T3 (da) 2001-10-30 2006-11-13 Novartis Ag Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
CA2673038C (en) 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
PL2173752T5 (pl) 2007-06-13 2022-12-05 Incyte Holdings Corporation Sole (r)-3-(4-(7h-pirolo(2,3-d)pirymidyn-4-ylo)-1h-pirazol-1-ilo)-3-cyklopentylopropanonitrylu inhibitora kinazy janusowej
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
EA017218B1 (ru) 2008-03-11 2012-10-30 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak-киназ
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
MX2011012262A (es) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP2486041B1 (en) 2009-10-09 2013-08-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US20110207754A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
UA109131C2 (ru) 2010-04-14 2015-07-27 Еррей Біофарма Інк. 5,7-ЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-c]ПИРИМИДИНЫ КАК ИНГИБИТОРЫ JAK-КИНАЗ
DK2574168T3 (en) 2010-05-21 2016-05-09 Incyte Holdings Corp Topical formulation to a jak inhibitor
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
WO2012116248A1 (en) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8962608B2 (en) 2011-09-22 2015-02-24 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
PE20151141A1 (es) 2012-11-01 2015-08-06 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
MX2015011667A (es) 2013-03-06 2015-12-16 Incyte Corp Procesos e intermedios para hacer un inhibidor de jak.
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
TWI664176B (zh) 2013-05-17 2019-07-01 英塞特公司 作為ｊａｋ抑制劑之聯吡唑衍生物
WO2014184328A1 (en) 2013-05-17 2014-11-20 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
JP2016528288A (ja) 2013-08-20 2016-09-15 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 上昇したｃ反応性タンパク質レベルを有する固形腫瘍の患者における延命効果
AU2014339897A1 (en) * 2013-10-24 2016-04-21 Abbvie Inc. JAK1 selective inhibitor and uses thereof
DK3110409T3 (en) 2014-02-28 2018-10-22 Incyte Corp JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
EP3137471A1 (en) 2014-04-30 2017-03-08 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP6697466B2 (ja) 2014-12-16 2020-05-20 ノバルティス アーゲー ＬｐｘＣ阻害剤としてのイソオキサゾールヒドロキサム酸化合物
MA43377A (fr) 2015-12-04 2021-05-19 Hutchinson Fred Cancer Res Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
ES2907557T3 (es) 2016-03-22 2022-04-25 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Métodos de intervención temprana para prevenir o mejorar la toxicidad
JP7219376B2 (ja) 2016-07-15 2023-02-08 ノバルティス アーゲー キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
WO2019040706A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING VITILIGO
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
SG11202007805SA (en) * 2018-02-16 2020-09-29 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
US11624751B2 (en) * 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
AR122505A1 (es) 2020-06-02 2022-09-14 Incyte Corp Procesos para preparar un inhibidor de jak1
JP2023552424A (ja) 2020-12-04 2023-12-15 インサイト・コーポレイション 皮膚疾患の治療のためのビタミンｄ類似体を有するｊａｋ阻害剤
TW202308610A (zh) 2021-05-03 2023-03-01 美商英塞特公司 用於治療結節性癢疹之ｊａｋ１途徑抑制劑

Also Published As

Publication number Publication date
IL303238A (en) 2023-07-01
US20220175731A1 (en) 2022-06-09
CL2023001637A1 (es) 2023-12-15
AU2021396231A9 (en) 2024-02-08
AU2021396231A1 (en) 2023-06-22
KR20230118118A (ko) 2023-08-10
WO2022125670A1 (en) 2022-06-16
EP4259131A1 (en) 2023-10-18
US11957661B2 (en) 2024-04-16
TW202237089A (zh) 2022-10-01
CA3204374A1 (en) 2022-06-16
JP2023552452A (ja) 2023-12-15

Similar Documents

Publication Publication Date Title
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
IL288395A (en) Mat2a tricyclic inhibitors and methods for use in cancer therapy
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
MX2022001004A (es) Inhibidores de enzimas.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
MX2021012418A (es) Compuestos heterociclicos y sus usos.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2022002069A (es) Inhibidores de enzimas.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.